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Poster Session-II 123low-dose TBI with (n 5 45) or without (n 5 17) fludarabine, or cy-
clophosphamide plus fludarabine (n 5 12). T-reg (CD41FoxP31)
levels on days 40, 100, 180 and 365 were determined by flow cytom-
etry. Chimerism levels among total white blood cells, CD31 T-cells
andCD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels.
Results:Mean Treg (6 SD) levels in controls were 316 18 cells/
mL.Mean (6 SD) Treg levels on day 100 were 206 24 cells /mL (p\
0.01 in comparison to controls) in patients without grade II-IV acute
GVHD before day 100, and 27 6 21 cells/mL (NS) in patients with
an antecedent of grade II-IV acute GVHD. Mean 6 donor CD31
T-cells and Treg chimerism levels on day 100 were 75 6 29% and
81 6 18%, respectively (NS). Day 100 chimerism levels among
CD31 T-cells and Tregs were highly correlated (r 5 0.78, p \
0.01). The 1-year probability of grade II-III NIH chronic GVHD
in patients with day 100 Treg levels below or above median was
53% and 36%, respectively (P 5 0.13). SjTREC levels significantly
increased from day 100 to day 365 after HCT (p\ 0.01), demon-
strating thymic recovery. Finally, Treg and sjTREC levels correlated
on days 100 (r 5 0.48, p\ 0.01) and 365 (r 5 0.47, p\ 0.01) after
HCT.
Conclusions: Our data did not show thus far a significant corre-
lation between Treg levels and occurrence of chronic GVHD. The
association between Treg and TREC levels on days 100 and 365
might suggest a role for the thymus in regulating Tregs levels after
HCT, or that similar factors affect thymic function and Treg levels
after nonmyeloablative conditioning. Data including higher number
of patients will be presented.343
GENERATION OF CLL-SPECIFIC CTL EFFECTORS FROM PARTIALLY HLA-
MATCHED UMBILICAL CORD BLOOD GRAFTS USING CD154-TRANS-
DUCED CLL CELL S AS APCS
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sity of Texas MD Anderson Cancer Center, Houston, TX; 2University of
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Introduction: Long-term remissions have been observed follow-
ing allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for the treatment of chronic lymphocytic leukemia (CLL). Unfortu-
nately, many CLL patients are ineligible for transplant due to the
lack of an HLA-compatible donor. Umbilical cord blood (UCB)
HSCT permits transplantation of many individuals who are ineligi-
ble for allo-HSCTdue to its reduced requirement for stringentHLA
matching; however, disease relapse remains a significant complica-
tion. Further, unlike allo-HSCT, donor lymphocyte infusion
(DLI) cannot be employed as a post-transplant therapy. To address
this issue we are developing a strategy to generate CLL-specific
T-lymphocytes to be employed as a post-UCB-HSCT therapeutic
treatment.
Methods:CLL-specific antigen presenting cells (APC) were gen-
erated by the transduction of CLL cells with an adenoviral vector en-
coding CD154 (CD40L). Successful transduction and subsequent
CD40 ligation in CLL cells were verified by monitoring CD95 ex-
pression. CLL APCwere then used to prime partially HLAmatched
(typically 4/6) UCB lymphocytes in the presence of IL-12, IL-2,
IL-7, and IL-15. Expanded UCB lymphocytes were phenotyped by
flow cytometry, and CLL specificity was determined by ELISpot
and 51Cr lysis using non-CLL (CD19-/CD31) patient lymphocytes
as allo-antigen controls.
Results: Effector cell phenotype was predominantly (.80%)
CD41; however, skewing towardCD81 expansion could be achieved
by incubation in IL-12 during priming. Significant populations of ef-
fector memory (CD62L1CD1271) and central memory
(CD62L-CD1271) cells were observed following repeated stimula-
tions with CLL-APC. Significant expansion (.4 fold) of UCB lym-
phocyte populations was typically observed. In ELISpot assays,
CLL-APC primed UCB lymphocyte responders exhibited a signifi-
cant increase (p . 0.05) in IFN-g ELISpots when incubated with
CLL stimulators in comparison to non-CLL control stimulators.Cytolytic activity was demonstrated against unmodified CLL cells
by 51Cr release assays in which percent lysis of CLL targets was
30–50% at E:T ratios of 10:1 and 20:1. Lysis of autologous non-
CLL control targets was negligible.
Conclusions: Our results demonstrate that in vitro generation of
CLL-specific effectors from partially HLA-matched UCB lympho-
cytes is both feasible and practical. These preclinical results support
further exploration of this technique as a promising treatment mo-
dality in conjunction with UCB-HSCT.344
THE T CELL CYTOLYTIC MOLECULES FAS LIGAND AND TRAIL, THE TRAF-
FICKING MOLECULES CCR9, 7 INTEGRIN AND PSGL1, AND THE IMMUNE
MODULATING MOLECULES OX40 AND CEACAM1 ARE REQUIRED FOR
THYMIC GRAFT-VERSUS-HOST DISEASE
Lu, S.X., Na, I.-K., Goldberg, G.L., Ghosh, A., Hirschhorn-
Cymerman, D., King, C.G., Smith, O.M., Suh, D., Rao, U., Yim, N.,
Holland, A.M., Penack, O., Jenq, R.R., Teisch, L., Meykler, S., Lin, J.,
Sepulveda, A., Merghoub, T., Houghton, A.N., van den Brink, M.R.M.
Memorial Sloan-Kettering Cancer Center, New York, NY
Thymic graft-versus-host-disease (tGVHD) contributes to im-
paired T cell reconstitution after allogeneic bone marrow transplan-
tation, but its pathophysiology has not been well defined. We
assessed thymic output (RAG21 splenic recent thymic emigrants)
as well as the thymic cellularity (esp. CD41CD81 cells) and found
that these were inversely related to numbers of mature donor T cells
in the allograft. Bcl-2 expression in donor BM-derived thymocytes
was decreased in recipients with GVHD vs. those without GVHD,
which suggests that survival of thymocytes is decreased during
tGVHD. Consequently, tGVHD severity may be associated with
thymic function We studied the migration of alloreactive donor T
cells in vivo and found that donor T cells infiltrated the thymus
within the first week post-transplant. Upon adoptive transfer of
CFSE-labeled donor T cells we noted that thymus-infiltrating allor-
eactive donorT cells were fast-proliferating (CFSElo) and highly ac-
tivated (CD251CD441). We then analyzed T cell trafficking in
tGVHDwithmice deficient for certain traffickingmolecules, and as-
sessed tGVHD by loss of BM-derived CD41CD81 thymocytes.
We found that CCR9, b7 integrin, and PSGL1 were all partially re-
quired for tGVHD, while L-selectin and aE integrin may be dis-
pensable. Similarly, we examined the role of T cell cytolytic
pathways for tGVHD, and found that FasL and TRAIL were re-
quired for tGVHD, but that perforin andTNFwere dispensable. Fi-
nally, we assessed the role of various T cell regulatory molecules for
tGVHD, and found that Ceacam1 and OX40 were required, while
GITR was partially required and ICOS was dispensable. Host
non-hematopoietic thymic stroma may be an important target for
donor alloreactive T cells in GVH reaction models. We assessed
the expression of the death receptors Fas and DR5 in thymic stroma
fromnormal and irradiated (8.5Gy) BALB/cmice, and observed that
in particular, MHC class II-negative stroma (endothelial cells and fi-
broblasts), as well as a population of MHC class II-positive stroma
(epithelial cells) upregulated the expression of both Fas and DR5 af-
ter irradiation. Thymic epithelial cell numbers were relatively pre-
served after irradiation of mice deficient for TRAIL and FasL. In
conclusion, we found that TRAIL, TNF, CCR9, integrin b7,
PSGL1, Ceacam1 and OX40 on donor T cells as important for
tGVHD pathophysiology. These data suggest selective therapeutic
targets to attenuate tGVHD and improve post-transplant T-cell re-
constitution.345
ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE SCORING USING THE NIH
CONSENSUS CRITERIA
Treister, N.1,2, Stevenson, K.2, Kim, H.2, Cutler, C.2 1Brigham and
Women’s Hospital; 2Dana-Farber Cancer Institute
Background: The NIH Oral cGVHD Activity Assessment In-
strument is intended to be simple to use and to provide a reproducible
objective measure of disease activity over time. The objective of this
studywas to assess inter- and intra-observer variability in the compo-
nent and composite scores in patients evaluated with oral cGVHD.
124 Poster Session-IIMethods: 24 clinicians, (‘‘non-expert MD’’, n 5 16; ‘‘non-expert
non-MD’’; n5 4; and oral ‘‘expert’’, n5 4), from six major transplant
centers scored high-quality intraoral photographs of 12 patients.
The same photographs were evaluated 1 week later by the same eval-
uators. An intra-class correlation coefficient (ICC) was used to calcu-
late intra-rater reliability and inter-rater agreement was analyzed
using a weighted k statistic: 0 # k # 0.20 5 poor, 0.21 # k # 0.40
5 fair, 0.41 # k # 0.60 5 moderate, 0.61 # k # 0.80 5 good,
0.81 # k # 1.00 5 very good. Data on participant experiences and
demographics were also collected.
Results:Mean inter-rater reliability for each element was poor to
moderate (range 0.15 – 0.46). Overall mean kappa scores were high-
est for ULCERS (0.46), followed by ERYTHEMA (0.23) and lowest
for LICHENOID (0.15) and MUCOCELES (0.14). Kappa scores
were higher in ‘‘expert’’ compared with ‘‘non-expert MD’’ and
‘‘non-expert non-MD’’ in ULCERS and ERYTHEMA (e.g. 0.85,
0.44, 0.33 for ULCERS, respectively), but similar in LICHENOID
and MUCOCELES. Overall intra-rater reliability in all groups was
very good ($0.90) and highest for ULCERS (0.97, 0.85, 0.94).
While 75% of ‘‘experts’’ were comfortable with their abilities to score
the cases, approximately 50% of ‘‘non-experts’’ were uncomfortable.
The majority felt that their evaluations were accurate, however
84% agreed that formal training is required.
Conclusions: Inter-rater variability of the oral cGVHD instru-
ment is unacceptable for the purposes of clinical trials. Greater con-
cordance among ‘‘experts’’, high intra-rater reliability, and
participant feedback suggests that formal training may significantly
decrease variability. Parallel investigations must be completed using
the other organ specific instruments prior to any revision and wide-
spread prospective utilization of these tools as research endpoints.346
INTERACTIONS BETWEEN DC AND T-CELLS INITIATE COUNTER-REGU-
LATORY IMMUNE ACTIVITIES THAT LIMITS AMPLIFICATION OF ALLO-IM-
MUNE RESPONSES AND GvHD
Lu, Y., Li, J.-M., Harris, W., Waller, E. Winship Cancer Institute,
Emory University, Atlanta, GA
Acute graft-versus-host disease (GvHD) remains a major compli-
cation following allogenic hematopoietic stem cell transplant
(HSCT). Our reports and several publications have suggested a po-
tential beneficial effect of donorDCduringHSCT.Using allogeneic
MHC-mismatched HSCTmice model, we previously demonstrated
that recipients transplanted with FACS-purified CD11b- DC with
HSC and T-cells had increased GvL and limited GvHD. In the cur-
rent study, we found that transplantation of T-cells from IFN-g
knock-out mice resulted in severe GvHD and higher levels of Th17
cells compared with recipients of T-cells from wide-type (WT)
mice, suggesting that donor T-cell synthesis of IFN-g induced by
donor DC is necessary to augment expansion of allo-reactive T-cells
that mediate GvL while subsequently limiting generalized activation
of donorT-cells that lead to off-target effects andGvHD. In order to
further clarify themechanisms involved in the action of donorDCon
the limitation of GvHD, we detected the level of the IFN-g-induc-
ible indoleamine-2,3-dioxygenase(IDO) protein, which has been re-
ported to exert inhibitory effects on T cells activity, on donor DCs
and its potential roles in regulating donor T cell allo-immune activ-
ity. We set up an in vitro co-culture system including purified
CD11b- DC from WT or IDO knock-out mice and CFSE-labeled
syngeneic T cells in the presence of allogeneic antigen. T-cells co-
cultured with CD11b- DC had higher proliferation rates compared
with T-cells cultured with allo-antigen in the absence of DCs. Fur-
thermore, CD8 T-cells proliferated earlier and more than CD4
T-cells in response to alloantigen in the presence of CD11b- DC,
suggesting CD8 T-cells be mainly responsible for the observed
GvL activity in murine model systems. IDO expression on WT
CD11b- DC was increased in 3–7 day cultures containing syngeneic
T cells and allo-antigen but not on DC cultured with allo-antigen
alone. Thus, IFN-g-induced IDO expression on CD11b- donor
DCs might be a critical downstream event that inhibits continued
T-cell activation by initiating counter-regulatory immune activities
that limit allo-immune responses. Interestingly, T cells co-cultured
with CD11b1DC from IDO knock-out donors had higher prolifera-tion rate than T cells co-cultured with CD11b- DC on day-7. Fur-
ther studies using IDO knock-out mice as DC donors in our
C57BL/6/B10.BR transplant model are essential to understand
the role of IDO expression of DC in allogeneic HSCT.347
INHIBITION OF GSK3 AND mTOR ENHANCES THE STEMNESS OF ACTI-
VATED CD81 T CELLS
Kato, K.1, Cui, S.1, Mineishi, S.1, Kuick, R.2, Huagh, J.3, Klein, P.3,
Reddy, P.1, Ferrara, J.1,2, Emerson, S.G.3,4, Zhang, Y.1 1University of
Michigan, Ann Arbor, MI; 2niversity of Michigan, Ann Arbor, MI;
3Univesrity of Pennsylvania, Philadelphia, PA; 4Haverford College, Phil-
adelphia, PA
Memory T cells have the ability to vigorously proliferate and to
generate differentiated effector cells upon reencounter of the cog-
nate antigen, while self-renewing. This stemness property of mem-
ory T cells has been explored for adoptive T cell immunotherapy.
On the other hand, it may be particularly difficult to treat memory
T cell-mediated inflammatory disorders, such as graft-versus-host
disease (GVHD) among others, unless long-lived memory T cells
are effectively targeted. However, the molecular mechanisms that
regulate the stemness of memory T cells remain unknown. Using
mouse GVHD models, we have previously identified a population
of alloreactive postmitotic CD44loCD62LhiCD81 memory T cells
(TPM) that induce GVHD. These TPM cells are able to generate
all subsets of effector and memory T cells and have greater ability
than both effectormemoryT cells (TEM) and centralmemoryT cells
(TCM) to proliferate, while self-renewing. These data suggest that
TPM cells contain higher frequency of T memory stem cells than
other memory T cell subsets. In the present study, we found that
these TPM cells were initially generated during host antigen-priming
of donor T cells and persisted throughout the disease course. Gene
microarray analysis revealed that TPM cells represented the earliest
antigen-experienced CD81 T cells to become effector and memory
T cells, whereas TEM cells were terminally differentiated cells. As
comparison, TCM cells were the intermediates between TPM cells
and TEM cells. Interestingly, during differentiation of TPM cells to
TEM cells, Wnt-signaling activity was dramatically decreased,
whereas mTOR activity was augmented. A similar molecular profil-
ing of alloreactive T cells was also found in activated TCR-trans-
genic CD81 T cells specific to LCMV gp33 peptide. Inhibition of
either GSK3 or mTOR during antigenic-priming of CD81 T cells
significantly enhanced the generation of memory T cells specific to
gp33 peptide. Thus, both GSK3- and mTOR-mediated signals
play important roles in regulating the stemness of activated CD81
T cells. These findings have significant implications in the develop-
ment of newmethods to treat ongoingGVHDand to augment adop-
tive T cell cancer therapy.348
OPTIMIZATION OF ALEMTUZUMAB DOSE FOR GRAFT-VERSUS-HOST DIS-
EASE PROPHYLAXIS FOR REDUCED INTENSITY TRANSPLANTATION
FROM UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC
MALIGNANCIES
Gupta, V.1, Xu, W.2, Sutherland, R.3, Kamel-Reid, S.3, Kuruvilla, J.1,
Loach, D.1, Lipton, J.H.1, Messner, H.A.1 1Princess Margaret Hospital,
Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Can-
ada; 3University Health Network, Toronto, ON, Canada
It has been shown that a high dose of alemtuzumab (100mg) in
combination with cyclosporine (CsA) significantly reduces the risk
of acute and chronic GVHD, however a high risk of relapse compro-
mises the transplant outcomes.We hypothesized that a lower dose of
alemtuzumab for GVHD prophylaxis may help in achieving a bal-
ance between prevention of severe GVHD while preserving
a Graft-versus-leukemia (GVL) effect.We studied the use of a lower
dose of alemtuzumab with CsA as GVHD prophylaxis in 36 patients
undergoing reduced intensity conditioning (RIC) usingmatched un-
related donors. The study includes two sequential cohorts treated at
Princess Margaret Hospital between September 2004 and July 2007:
cohort 1 (n 5 17) received 60 mg of IV alemtuzumab (10mg, 20mg
and 30 mg on days –8,27 and –6); cohort 2 (n5 19) received 30 mg
